Skip to main content
SpringerLink
Log in

Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the usefulness of daptomycin, tigecycline, and linezolid for the treatment of MRSA infection compared with vancomycin in Belgium, the United Kingdom/Ireland, and Spain.

Methods

The methodology included the following steps: acquisition of microbiological and pharmacokinetic data, Monte Carlo simulation, estimation of the probability of target attainment (PTA), and calculation of the cumulative fraction of response (CFR).

Results

We showed that differences in the susceptibility of MRSA strains among countries may justify differences in the antibiotic dose selection. Two, 3, and 4 g daily of vancomycin seem be adequate in Belgium, Spain, and United Kingdom/Ireland respectively. The CFR obtained with 50 mg tigecycline every 12 h was higher in Spain than in Belgium and the United Kingdom/Ireland, but with the highest dose (100 mg q12h) the CFR was always 100%. At least 8 mg/kg daptomycin is necessary in United Kingdom/Ireland, but 4 mg/kg may be sufficient in Spain, and probably in Belgium. Six hundred mg q12h linezolid may be adequate in the four countries.

Conclusion

Our study reinforces the idea that the local MIC distribution must be considered in order to increase the probability of success of empirical treatment and must be periodically updated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Tiemersma EW, Bronzwaer SL, Lyytikäinen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H, European Antimicrobial Resistance Surveillance System Participants (2004) Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 10:1627–1634

    Article  PubMed  Google Scholar 

  2. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352:1436–1444

    Article  PubMed  CAS  Google Scholar 

  3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, Active Bacterial Core surveillance (ABCs) MRSA Investigators (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763–1771

    Article  PubMed  CAS  Google Scholar 

  4. Rodríguez-Baño J, Domínguez MA, Millán AB, Borraz C, González PM, Almirante B, Cercenado E, Padilla B, Pujol M, GEIH/GEMARA (SEIMC); REIPI (2009) Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain. Clin Microbiol Infect 15:1111–1118

    Article  PubMed  Google Scholar 

  5. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S (2009) Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 15:125–136

    Article  PubMed  CAS  Google Scholar 

  6. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, Kluytmans J, Bonten M, European Practices of Infections with Staphylococcus aureus (SEPIA) Study Group (2009) Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 49:997–1005

    Article  PubMed  CAS  Google Scholar 

  7. Scaglione F, Paraboni L (2008) Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. Int J Antimicrob Agents 32:294–301

    Article  PubMed  CAS  Google Scholar 

  8. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC, Infectious Diseases Society of America (2005) Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 15:1373–1406

    Article  Google Scholar 

  9. Kollef MH, Napolitano LM, Solomkin JS, Wunderink RG, Bae IG, Fowler VG, Balk RA, Stevens DL, Rahal JJ, Shorr AF, Linden PK, Micek ST (2008) Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis 47 [Suppl 2]:S55–S99

    Article  PubMed  CAS  Google Scholar 

  10. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak M, Talan DA, Chambers HF (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285–292

    Article  PubMed  Google Scholar 

  11. Simor AE, Loeb M, CIDS/CAMM Guidelines Committee (2004) The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper. Can J Infect Dis 15:39–48

    PubMed  Google Scholar 

  12. Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, Lewis D, British Society for Antimicrobial Chemotherapy Working Party on Community-onset MRSA Infections (2008) Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61:976–994

    Article  PubMed  CAS  Google Scholar 

  13. Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, Cleverley J, Dilworth P, Fry C, Gascoigne AD, Knox A, Nathwani D, Spencer R, Wilcox M (2008) Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 62:5–34

    Article  PubMed  CAS  Google Scholar 

  14. Kalenić S, Pal MP, Palcevski VV, Horvatić J, Mestrović T, Barsić B, Stamenić V, Aleraj B, Buljan M, Grzalja N, Burcar I, Korusić A, Vucić M, Civljak R, Stancić M, Budimir A (2008) Guidelines for prevention, control and treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Lijec Vjesn 130 [Suppl 1]:7–32

    PubMed  Google Scholar 

  15. Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D, Ridgway GL, Spry MJ, Warren RE; MRSA Working Party of the British Society for Antimicrobial Chemotherapy (2009) Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63:849-861

    Article  PubMed  CAS  Google Scholar 

  16. Mensa J, Barberán J, Llinares P, Picazo J, Bouza E, Alvarez-Lerma F, Borges M, Serrano R, León C, Guirao X, Arias J, Carreras E, Sanz M, García-Rodríguez J, Sociedad Española de Quimioterapia, Sociedad Española de Medicina Interna, Sociedad Española de Medicina Interna, Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias, Asociacion Española de Cirujanos, Asociacion Española de Hematologia y Hemoterapia (2008) Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus. Rev Esp Quimioter 21:234–258

    PubMed  CAS  Google Scholar 

  17. Dryden M, Andrasevic AT, Bassetti M, Bouza E, Chastre J, Cornaglia G, Esposito S, French G, Giamarellou H, Gyssens IC, Nathwani D, Unal S, Voss A (2010) A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice (2010). Clin Microbiol Infect 16 [Suppl 1]:3-30.

    Article  PubMed  CAS  Google Scholar 

  18. Sievert DM, Wilson ML, Wilkins MJ, Gillespie BW, Boulton ML (2010) Public health surveillance for methicillin-resistant Staphylococcus aureus: comparison of methods for classifying health care- and community-associated infections. Am J Public Health 100:1777–1783

    Article  PubMed  Google Scholar 

  19. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM (2004) Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42:2398–2402

    Article  PubMed  CAS  Google Scholar 

  20. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr (2004) Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 38:1700–1705

    Article  PubMed  CAS  Google Scholar 

  21. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A (2006) High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 166:2138–2144

    Article  PubMed  Google Scholar 

  22. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J (2008) Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 46:193–200

    Article  PubMed  CAS  Google Scholar 

  23. Steinkraus G, White R, Friedrich L (2007) Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–5. J Antimicrob Chemother 60:788–794

    Article  PubMed  CAS  Google Scholar 

  24. Gould IM (2008) Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31 [Suppl 2]:1–9

    Article  PubMed  CAS  Google Scholar 

  25. Wang G, Hindler JF, Ward KW, Bruckner DA (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44:3883–3886

    Article  PubMed  CAS  Google Scholar 

  26. Reynolds R (2009) Antimicrobial resistance in the UK and Ireland. J Antimicrob Chemother 64 [Suppl 1]:19–23

    Article  Google Scholar 

  27. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49(3):325–327

    Article  PubMed  Google Scholar 

  28. Scaglione F, Paraboni L (2006) Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 4:479–490

    Article  PubMed  CAS  Google Scholar 

  29. Mouton JW, Vinks AA (2007) Continuous infusion of beta-lactams. Curr Opin Crit Care 13:598–606

    Article  PubMed  Google Scholar 

  30. Nicolau DP (2008) Pharmacodynamic optimization of beta-lactams in the patient care setting. Crit Care 12 [Suppl 4]:S2

    Article  PubMed  Google Scholar 

  31. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL (2005) Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 55:601–607

    Article  PubMed  CAS  Google Scholar 

  32. Denis O, Nonhoff C, Struelens MJ (2008) Microbiological Surveillance of Staphylococcus aureus in Belgian Hospitals in 2008. Final Report. http://www.erasme.ulb.ac.be/files/files/Microbiologie/LRStaph/report_surv_mrsa_2008.pdf. Accessed 5 December 2011.

  33. British Society for Antimicrobial Chemotherapy Resistance Surveillance Project. http://bsacsurv.org/. Accessed 1 December 2011.

  34. Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, López-Fabal F, Gómez M, the VIRA Study Group (2011) Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glypopeptide tolerance. Diagn Microbiol Infect Dis 70:373–379

    Article  PubMed  CAS  Google Scholar 

  35. Rushing TA, Ambrose PJ (2001) Clinical application and evaluation of vancomycin dosing in adults. J Pharm Technol 17:33–38

    CAS  Google Scholar 

  36. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C, MacGowan A, Shaw S, Kibbler C, Singer M, Wilson AP (2005) Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 55:333–340

    Article  PubMed  CAS  Google Scholar 

  37. Steenbergen JN, Alder J, Thorne GM, Alder J, Jones RN (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283–288

    Article  PubMed  CAS  Google Scholar 

  38. Benvenuto M, Benziger DP, Yankelev S, Vigliani G (2006) Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 50:3245–3249

    Article  PubMed  CAS  Google Scholar 

  39. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49:220–229

    Article  PubMed  CAS  Google Scholar 

  40. Bonate PL (2001) A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 40:15–22

    Article  PubMed  CAS  Google Scholar 

  41. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC (2004) Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 48:1713–1718

    Article  PubMed  CAS  Google Scholar 

  42. Sánchez Navarro A (2005) Pharmacokinetic/pharmacodynamic analysis to optimize antibacterial treatments: prediction of efficacy by using Montecarlo simulation techniques. Rev Esp Quimioter 18:230–235

    PubMed  Google Scholar 

  43. Oracle® Crystal Ball, Fusion Edition (Version 11.1.1.1.00). Crystal Ball User's Guide, 11.1.2. http://oracle.com/crystalball/index.html. Last accessed 16 August 2011.

  44. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82–98

    Article  PubMed  CAS  Google Scholar 

  45. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42:1411–1423

    Article  PubMed  CAS  Google Scholar 

  46. Andes D, van Ogtrop ML, Peng J, Craig WA (2002) In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 46:3484–3489

    Article  PubMed  CAS  Google Scholar 

  47. Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63–68

    Article  PubMed  CAS  Google Scholar 

  48. Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E (2009) Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 63:155–159

    Article  PubMed  CAS  Google Scholar 

  49. American Thoracic Society; Infectious Diseases Society of America (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171:388–416

    Article  Google Scholar 

  50. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America (2005) Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111:394–434

    Article  Google Scholar 

  51. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330–1336

    Article  PubMed  CAS  Google Scholar 

  52. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH (2007) A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 29:1107–1115

    Article  PubMed  CAS  Google Scholar 

  53. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH (2009) Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 34:570–574

    Article  PubMed  CAS  Google Scholar 

  54. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM (2009) Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 63:1050–1057

    Article  PubMed  CAS  Google Scholar 

  55. Gordts B, Firre E, Jordens P, Legrand JC, Maertens J, Struelens M, on behalf of the Infectious Diseases Advisory Board (2000) National guidelines for the judicious use of glycopeptides in Belgium. Clin Microbiol Infect 6:585–592

    Article  Google Scholar 

  56. Gudiol F, Aguado JM, Pascual A, Pujol M, Almirante B, Miró JM, Cercenado E, Domínguez Mde L, Soriano A, Rodríguez-Baño J, Vallés J, Palomar M, Tornos P, Bouza E, Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (2009) Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Enferm Infecc Microbiol Clin 27:105–115

    Article  PubMed  Google Scholar 

  57. Mendes RE, Sader SH, Farrell DJ, Jones RN (2011) Update on the telavancin activity tested against European staphylococcal clinical isolates (2009–2010). Diagn Microbiol Infect Dis 71:93–97

    Article  PubMed  CAS  Google Scholar 

  58. Sader HS, Jones RN (2009) Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008). Diagn Microbiol Infect Dis 65:158–162

    Article  PubMed  CAS  Google Scholar 

  59. Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid resistant Staphylococcus aureus. Clin Infect Dis 50:821–825

    Article  PubMed  CAS  Google Scholar 

  60. Denis O, Struelens MJ (2005) Microbiological Surveillance of Staphylococcus aureus in Belgian Hospitals in 2005. Final Report. http://www.erasme.ulb.ac.be/files/files/Microbiologie/LRStaph/report_surv_mrsa_2005.pdf. Accessed 5 December 2011

  61. Frei CR, Wiederhold NP, Burgess DS (2008) Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61:621–628

    Article  PubMed  CAS  Google Scholar 

  62. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP (2005) Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 25:935–941

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Departamento de Educación, Universidades e Investigación (IT341-10) and by the Departamento de Sanidad (2009111062), Gobierno Vasco, Spain.

Conflict of interest

None to declare.

Author information

Authors and Affiliations

  1. Microbiology Department, Hospital Universitario de Alava, Vitoria, Spain

    A. Canut

  2. Faculty of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad nº 7, 01006, Vitoria, Spain

    A. Isla & A. R. Gascón

  3. Microbiology Department, Hospital Clínico San Carlos, Madrid, Spain

    C. Betriu

  4. Pharmacokinetics, Nanotechnology and Gene Therapy Group, University of the Basque Country UPV/EHU, Paseo de la Universidad nº 7, 01006, Vitoria, Spain

    A. R. Gascón

Authors
  1. A. Canut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Betriu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. R. Gascón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. R. Gascón.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Canut, A., Isla, A., Betriu, C. et al. Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis 31, 2227–2235 (2012). https://doi.org/10.1007/s10096-012-1560-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-012-1560-7

Keywords

Search

Navigation